http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 09 Mar 2026 06:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Mar+03/26128244.html si-local-file:///var/storage/secattach/20260309/26128244.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Mar+03/26128244.html Mon, 09 Mar 2026 06:00:00 -0400 LGVN O.49866458 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Mar+03/26128244.html si-local-file:///var/storage/secattach/20260309/26128244.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Mar+03/26128244.html Mon, 09 Mar 2026 06:00:00 -0400 LGVN O.49866458 http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Longeveron+Inc.+++++++++++For%3A+Mar+03/26096764.html si-local-file:///var/storage/secattach/20260303/26096764.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Longeveron+Inc.+++++++++++For%3A+Mar+03/26096764.html Tue, 03 Mar 2026 08:00:00 -0400 LGVN O.49866458 http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Longeveron+Inc.+++++++++++For%3A+Mar+03/26096764.html si-local-file:///var/storage/secattach/20260303/26096764.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Longeveron+Inc.+++++++++++For%3A+Mar+03/26096764.html Tue, 03 Mar 2026 08:00:00 -0400 LGVN O.49866458 http://www.streetinsider.com/Corporate+News/Longeveron+publishes+Phase+2b+stem+cell+trial+results+in+Cell+Stem+Cell/26057444.html <p>Longeveron Inc. (NASDAQ: LGVN) announced that results from its Phase 2b clinical trial of laromestrocel, a mesenchymal stem cell therapy, were published in Cell Stem Cell journal. The study showed the treatment improved physical condition in patients with age-related frailty compared to placebo after nine months.</p><p>The randomized, dose-finding trial evaluated 148 ambulatory individuals with frailty. Results showed laromestrocel infusions led to increases in the primary endpoint of the 6-minute walk test compared with placebo, with a 63.4-meter improvement at month 9 and 41.3-meter improvement at month 6. The 9-month result reached statistical significance with a p-value of 0.0077.</p><p>The trial also http://www.streetinsider.com/Corporate+News/Longeveron+publishes+Phase+2b+stem+cell+trial+results+in+Cell+Stem+Cell/26057444.html Wed, 25 Feb 2026 11:05:30 -0400 LGVN LGVNR http://www.streetinsider.com/Corporate+News/Longeveron+publishes+Phase+2b+stem+cell+trial+results+in+Cell+Stem+Cell/26057444.html <p>Longeveron Inc. (NASDAQ: LGVN) announced that results from its Phase 2b clinical trial of laromestrocel, a mesenchymal stem cell therapy, were published in Cell Stem Cell journal. The study showed the treatment improved physical condition in patients with age-related frailty compared to placebo after nine months.</p><p>The randomized, dose-finding trial evaluated 148 ambulatory individuals with frailty. Results showed laromestrocel infusions led to increases in the primary endpoint of the 6-minute walk test compared with placebo, with a 63.4-meter improvement at month 9 and 41.3-meter improvement at month 6. The 9-month result reached statistical significance with a p-value of 0.0077.</p><p>The trial also http://www.streetinsider.com/Corporate+News/Longeveron+publishes+Phase+2b+stem+cell+trial+results+in+Cell+Stem+Cell/26057444.html Wed, 25 Feb 2026 11:05:30 -0400 LGVN LGVNR http://www.streetinsider.com/FDA/Longeveron+publishes+Phase+2b+stem+cell+trial+results+in+Cell+Stem+Cell/26057444.html <p>Longeveron Inc. (NASDAQ: LGVN) announced that results from its Phase 2b clinical trial of laromestrocel, a mesenchymal stem cell therapy, were published in Cell Stem Cell journal. The study showed the treatment improved physical condition in patients with age-related frailty compared to placebo after nine months.</p><p>The randomized, dose-finding trial evaluated 148 ambulatory individuals with frailty. Results showed laromestrocel infusions led to increases in the primary endpoint of the 6-minute walk test compared with placebo, with a 63.4-meter improvement at month 9 and 41.3-meter improvement at month 6. The 9-month result reached statistical significance with a p-value of 0.0077.</p><p>The trial also http://www.streetinsider.com/FDA/Longeveron+publishes+Phase+2b+stem+cell+trial+results+in+Cell+Stem+Cell/26057444.html Wed, 25 Feb 2026 11:05:30 -0400 LGVN LGVNR http://www.streetinsider.com/FDA/Longeveron+publishes+Phase+2b+stem+cell+trial+results+in+Cell+Stem+Cell/26057444.html <p>Longeveron Inc. (NASDAQ: LGVN) announced that results from its Phase 2b clinical trial of laromestrocel, a mesenchymal stem cell therapy, were published in Cell Stem Cell journal. The study showed the treatment improved physical condition in patients with age-related frailty compared to placebo after nine months.</p><p>The randomized, dose-finding trial evaluated 148 ambulatory individuals with frailty. Results showed laromestrocel infusions led to increases in the primary endpoint of the 6-minute walk test compared with placebo, with a 63.4-meter improvement at month 9 and 41.3-meter improvement at month 6. The 9-month result reached statistical significance with a p-value of 0.0077.</p><p>The trial also http://www.streetinsider.com/FDA/Longeveron+publishes+Phase+2b+stem+cell+trial+results+in+Cell+Stem+Cell/26057444.html Wed, 25 Feb 2026 11:05:30 -0400 LGVN LGVNR http://www.streetinsider.com/Press+Releases/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html <p align="justify">MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MfQVXZ8tHLoGIPk_2lgcdknuVEZ5vRrftmNcsmHLgp2rcLodtgkc_qnRQtU7Srj3-WneMqxKg6Rbkdoq9vNkKyLHMJPxkpCIo5JWDFYMfEk=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Lk0v-pA2eizS7_MUQZ6F1Rd30VdLQu75SAIiuXZJ4in-xX4_GynaYfaJ3N4pKREXYKmtviStvNMPPCWl0yHQJirwVohdnlH_YhCerU2wafimxmAs2AxJ-7lD6ye2lFee" rel="nofollow" target="_blank">Cell Stem Cell</a>, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. The full publication is available on the <em>Cell Stem Cell</em> website http://www.streetinsider.com/Press+Releases/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html Wed, 25 Feb 2026 11:05:00 -0400 A.50213784 LGVN LGVNR O.08407916 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html <p align="justify">MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MfQVXZ8tHLoGIPk_2lgcdknuVEZ5vRrftmNcsmHLgp2rcLodtgkc_qnRQtU7Srj3-WneMqxKg6Rbkdoq9vNkKyLHMJPxkpCIo5JWDFYMfEk=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Lk0v-pA2eizS7_MUQZ6F1Rd30VdLQu75SAIiuXZJ4in-xX4_GynaYfaJ3N4pKREXYKmtviStvNMPPCWl0yHQJirwVohdnlH_YhCerU2wafimxmAs2AxJ-7lD6ye2lFee" rel="nofollow" target="_blank">Cell Stem Cell</a>, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. The full publication is available on the <em>Cell Stem Cell</em> website http://www.streetinsider.com/Press+Releases/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html Wed, 25 Feb 2026 11:05:00 -0400 A.50213784 LGVN LGVNR O.08407916 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html <p align="justify">MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MfQVXZ8tHLoGIPk_2lgcdknuVEZ5vRrftmNcsmHLgp2rcLodtgkc_qnRQtU7Srj3-WneMqxKg6Rbkdoq9vNkKyLHMJPxkpCIo5JWDFYMfEk=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Lk0v-pA2eizS7_MUQZ6F1Rd30VdLQu75SAIiuXZJ4in-xX4_GynaYfaJ3N4pKREXYKmtviStvNMPPCWl0yHQJirwVohdnlH_YhCerU2wafimxmAs2AxJ-7lD6ye2lFee" rel="nofollow" target="_blank">Cell Stem Cell</a>, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. The full publication is available on the <em>Cell Stem Cell</em> website http://www.streetinsider.com/Press+Releases/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html Wed, 25 Feb 2026 11:05:00 -0400 A.50213784 LGVN LGVNR O.08407916 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html <p align="justify">MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MfQVXZ8tHLoGIPk_2lgcdknuVEZ5vRrftmNcsmHLgp2rcLodtgkc_qnRQtU7Srj3-WneMqxKg6Rbkdoq9vNkKyLHMJPxkpCIo5JWDFYMfEk=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Lk0v-pA2eizS7_MUQZ6F1Rd30VdLQu75SAIiuXZJ4in-xX4_GynaYfaJ3N4pKREXYKmtviStvNMPPCWl0yHQJirwVohdnlH_YhCerU2wafimxmAs2AxJ-7lD6ye2lFee" rel="nofollow" target="_blank">Cell Stem Cell</a>, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. The full publication is available on the <em>Cell Stem Cell</em> website http://www.streetinsider.com/Press+Releases/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html Wed, 25 Feb 2026 11:05:00 -0400 A.50213784 LGVN LGVNR O.08407916 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html <p align="justify">MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MfQVXZ8tHLoGIPk_2lgcdknuVEZ5vRrftmNcsmHLgp2rcLodtgkc_qnRQtU7Srj3-WneMqxKg6Rbkdoq9vNkKyLHMJPxkpCIo5JWDFYMfEk=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Lk0v-pA2eizS7_MUQZ6F1Rd30VdLQu75SAIiuXZJ4in-xX4_GynaYfaJ3N4pKREXYKmtviStvNMPPCWl0yHQJirwVohdnlH_YhCerU2wafimxmAs2AxJ-7lD6ye2lFee" rel="nofollow" target="_blank">Cell Stem Cell</a>, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. The full publication is available on the <em>Cell Stem Cell</em> website http://www.streetinsider.com/Press+Releases/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html Wed, 25 Feb 2026 11:05:00 -0400 A.50213784 LGVN LGVNR O.08407916 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html <p align="justify">MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MfQVXZ8tHLoGIPk_2lgcdknuVEZ5vRrftmNcsmHLgp2rcLodtgkc_qnRQtU7Srj3-WneMqxKg6Rbkdoq9vNkKyLHMJPxkpCIo5JWDFYMfEk=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Lk0v-pA2eizS7_MUQZ6F1Rd30VdLQu75SAIiuXZJ4in-xX4_GynaYfaJ3N4pKREXYKmtviStvNMPPCWl0yHQJirwVohdnlH_YhCerU2wafimxmAs2AxJ-7lD6ye2lFee" rel="nofollow" target="_blank">Cell Stem Cell</a>, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. The full publication is available on the <em>Cell Stem Cell</em> website http://www.streetinsider.com/Globe+Newswire/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html Wed, 25 Feb 2026 11:05:00 -0400 A.50213784 LGVN LGVNR O.08407916 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html <p align="justify">MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MfQVXZ8tHLoGIPk_2lgcdknuVEZ5vRrftmNcsmHLgp2rcLodtgkc_qnRQtU7Srj3-WneMqxKg6Rbkdoq9vNkKyLHMJPxkpCIo5JWDFYMfEk=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Lk0v-pA2eizS7_MUQZ6F1Rd30VdLQu75SAIiuXZJ4in-xX4_GynaYfaJ3N4pKREXYKmtviStvNMPPCWl0yHQJirwVohdnlH_YhCerU2wafimxmAs2AxJ-7lD6ye2lFee" rel="nofollow" target="_blank">Cell Stem Cell</a>, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. The full publication is available on the <em>Cell Stem Cell</em> website http://www.streetinsider.com/Globe+Newswire/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html Wed, 25 Feb 2026 11:05:00 -0400 A.50213784 LGVN LGVNR O.08407916 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html <p align="justify">MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MfQVXZ8tHLoGIPk_2lgcdknuVEZ5vRrftmNcsmHLgp2rcLodtgkc_qnRQtU7Srj3-WneMqxKg6Rbkdoq9vNkKyLHMJPxkpCIo5JWDFYMfEk=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Lk0v-pA2eizS7_MUQZ6F1Rd30VdLQu75SAIiuXZJ4in-xX4_GynaYfaJ3N4pKREXYKmtviStvNMPPCWl0yHQJirwVohdnlH_YhCerU2wafimxmAs2AxJ-7lD6ye2lFee" rel="nofollow" target="_blank">Cell Stem Cell</a>, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. The full publication is available on the <em>Cell Stem Cell</em> website http://www.streetinsider.com/Globe+Newswire/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html Wed, 25 Feb 2026 11:05:00 -0400 A.50213784 LGVN LGVNR O.08407916 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html <p align="justify">MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MfQVXZ8tHLoGIPk_2lgcdknuVEZ5vRrftmNcsmHLgp2rcLodtgkc_qnRQtU7Srj3-WneMqxKg6Rbkdoq9vNkKyLHMJPxkpCIo5JWDFYMfEk=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Lk0v-pA2eizS7_MUQZ6F1Rd30VdLQu75SAIiuXZJ4in-xX4_GynaYfaJ3N4pKREXYKmtviStvNMPPCWl0yHQJirwVohdnlH_YhCerU2wafimxmAs2AxJ-7lD6ye2lFee" rel="nofollow" target="_blank">Cell Stem Cell</a>, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. The full publication is available on the <em>Cell Stem Cell</em> website http://www.streetinsider.com/Globe+Newswire/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html Wed, 25 Feb 2026 11:05:00 -0400 A.50213784 LGVN LGVNR O.08407916 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html <p align="justify">MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MfQVXZ8tHLoGIPk_2lgcdknuVEZ5vRrftmNcsmHLgp2rcLodtgkc_qnRQtU7Srj3-WneMqxKg6Rbkdoq9vNkKyLHMJPxkpCIo5JWDFYMfEk=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Lk0v-pA2eizS7_MUQZ6F1Rd30VdLQu75SAIiuXZJ4in-xX4_GynaYfaJ3N4pKREXYKmtviStvNMPPCWl0yHQJirwVohdnlH_YhCerU2wafimxmAs2AxJ-7lD6ye2lFee" rel="nofollow" target="_blank">Cell Stem Cell</a>, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. The full publication is available on the <em>Cell Stem Cell</em> website http://www.streetinsider.com/Globe+Newswire/Longeveron%C2%AE+Results+of+Phase+2b+Clinical+Trial+Demonstrating+Stem+Cell+Therapy+Improved+Condition+of+Patients+with+Age-Related+Frailty+Published+in+Cell+Stem+Cell/26057437.html Wed, 25 Feb 2026 11:05:00 -0400 A.50213784 LGVN LGVNR O.08407916 O.49866458 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Feb+09/26001451.html si-local-file:///var/storage/secattach/20260213/26001451.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Feb+09/26001451.html Fri, 13 Feb 2026 16:46:00 -0400 LGVN O.49866458 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Feb+09/26001451.html si-local-file:///var/storage/secattach/20260213/26001451.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Feb+09/26001451.html Fri, 13 Feb 2026 16:46:00 -0400 LGVN O.49866458 http://www.streetinsider.com/Management+Changes/Longeveron+appoints+Stephen+Willard+as+CEO/26000906.html <p>Longeveron Inc. (NASDAQ: LGVN) announced that its board of directors appointed Stephen H. Willard as chief executive officer, effective February 11. Willard succeeds Than Powell, who served as interim CEO and will remain with the company to support the leadership transition and continue business development activities.</p> <p>Willard brings over 30 years of leadership experience in biotechnology and pharmaceutical companies. He previously served as CEO of ICAPATH Inc., NRx Pharmaceuticals Inc., Cellphire Inc., and Flamel Technologies S.A., a NASDAQ-traded biotech company where he served for seven years and was CFO before becoming CEO. He also served as chairman of Flamel's board and http://www.streetinsider.com/Management+Changes/Longeveron+appoints+Stephen+Willard+as+CEO/26000906.html Fri, 13 Feb 2026 16:30:25 -0400 A.02590357 A.15720578 A.36922931 A.50213784 LGVN LGVNR O.00343510 O.00840469 O.08407916 O.48361816 O.49866458 http://www.streetinsider.com/Management+Changes/Longeveron+appoints+Stephen+Willard+as+CEO/26000906.html <p>Longeveron Inc. (NASDAQ: LGVN) announced that its board of directors appointed Stephen H. Willard as chief executive officer, effective February 11. Willard succeeds Than Powell, who served as interim CEO and will remain with the company to support the leadership transition and continue business development activities.</p> <p>Willard brings over 30 years of leadership experience in biotechnology and pharmaceutical companies. He previously served as CEO of ICAPATH Inc., NRx Pharmaceuticals Inc., Cellphire Inc., and Flamel Technologies S.A., a NASDAQ-traded biotech company where he served for seven years and was CFO before becoming CEO. He also served as chairman of Flamel's board and http://www.streetinsider.com/Management+Changes/Longeveron+appoints+Stephen+Willard+as+CEO/26000906.html Fri, 13 Feb 2026 16:30:25 -0400 A.02590357 A.15720578 A.36922931 A.50213784 LGVN LGVNR O.00343510 O.00840469 O.08407916 O.48361816 O.49866458 http://www.streetinsider.com/Management+Changes/Longeveron+appoints+Stephen+Willard+as+CEO/26000906.html <p>Longeveron Inc. (NASDAQ: LGVN) announced that its board of directors appointed Stephen H. Willard as chief executive officer, effective February 11. Willard succeeds Than Powell, who served as interim CEO and will remain with the company to support the leadership transition and continue business development activities.</p> <p>Willard brings over 30 years of leadership experience in biotechnology and pharmaceutical companies. He previously served as CEO of ICAPATH Inc., NRx Pharmaceuticals Inc., Cellphire Inc., and Flamel Technologies S.A., a NASDAQ-traded biotech company where he served for seven years and was CFO before becoming CEO. He also served as chairman of Flamel's board and http://www.streetinsider.com/Management+Changes/Longeveron+appoints+Stephen+Willard+as+CEO/26000906.html Fri, 13 Feb 2026 16:30:25 -0400 A.02590357 A.15720578 A.36922931 A.50213784 LGVN LGVNR O.00343510 O.00840469 O.08407916 O.48361816 O.49866458 http://www.streetinsider.com/Management+Changes/Longeveron+appoints+Stephen+Willard+as+CEO/26000906.html <p>Longeveron Inc. (NASDAQ: LGVN) announced that its board of directors appointed Stephen H. Willard as chief executive officer, effective February 11. Willard succeeds Than Powell, who served as interim CEO and will remain with the company to support the leadership transition and continue business development activities.</p> <p>Willard brings over 30 years of leadership experience in biotechnology and pharmaceutical companies. He previously served as CEO of ICAPATH Inc., NRx Pharmaceuticals Inc., Cellphire Inc., and Flamel Technologies S.A., a NASDAQ-traded biotech company where he served for seven years and was CFO before becoming CEO. He also served as chairman of Flamel's board and http://www.streetinsider.com/Management+Changes/Longeveron+appoints+Stephen+Willard+as+CEO/26000906.html Fri, 13 Feb 2026 16:30:25 -0400 A.02590357 A.15720578 A.36922931 A.50213784 LGVN LGVNR O.00343510 O.00840469 O.08407916 O.48361816 O.49866458 http://www.streetinsider.com/Management+Changes/Longeveron+appoints+Stephen+Willard+as+CEO/26000906.html <p>Longeveron Inc. (NASDAQ: LGVN) announced that its board of directors appointed Stephen H. Willard as chief executive officer, effective February 11. Willard succeeds Than Powell, who served as interim CEO and will remain with the company to support the leadership transition and continue business development activities.</p> <p>Willard brings over 30 years of leadership experience in biotechnology and pharmaceutical companies. He previously served as CEO of ICAPATH Inc., NRx Pharmaceuticals Inc., Cellphire Inc., and Flamel Technologies S.A., a NASDAQ-traded biotech company where he served for seven years and was CFO before becoming CEO. He also served as chairman of Flamel's board and http://www.streetinsider.com/Management+Changes/Longeveron+appoints+Stephen+Willard+as+CEO/26000906.html Fri, 13 Feb 2026 16:30:25 -0400 A.02590357 A.15720578 A.36922931 A.50213784 LGVN LGVNR O.00343510 O.00840469 O.08407916 O.48361816 O.49866458